Minerals Therapeutics shares buy rating up to $45-Budrigantrade
2023.03.07 12:44
Minerals Therapeutics shares buy rating up to $45-Budrigantrade
By Ray Johnson
Budrigannews.com – Mineralys Therapeutics (NASDAQ:) received a Buy rating and a $45 per share price target from analysts at Budrigantrade on Tuesday, in a note to customers.
“Decades-long stasis, with the level of uncontrolled and resistant hypertension only rising,” the analysts stated of the hypertension market.
They wrote, “This losing battle is well-correlated with the global rise in obesity and the resulting rising levels of hyperaldosteronism-a well-known contributor.”
“Potentially ‘best-in-class,’ highly-selective aldosterone synthase inhibitor (ASI)—lorundrostat—in a new class of drugs targeted to patients with elevated aldosterone who could be better served than by another broadly-targeted incremental alternative,” however, analysts believe MLYS is directly addressing this issue with its product.
They explained that, “as validated by AstraZeneca’s recent acquisition of CinCor for $1.8bn (including CVR),” a broader return to macro-indications and the hyperaldosteronism “problem specifically” have sparked interest from large pharmaceutical companies.
The analysts came to the following conclusion: “We think MLYS has the potential for the same level of value accretion in a market with seemingly unlimited upside.”
